Skip to content
Screener

Karyopharm Therapeutics KPTI Q1 2026 earnings

Reported May 14, 2026 · Before market open

Revenue$35.1MBeat by $3.7M
EPS-$1.24Beat by $0.21
Revenue estimate$31.4M
EPS estimate-$1.45

Next report

Nov 2, 2026 (in a month)
Revenue estimate$33.5M
EPS estimate-$1.16

FAQ

When did Karyopharm Therapeutics report Q1 2026 earnings?
Karyopharm Therapeutics (KPTI) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Karyopharm Therapeutics's Q1 2026 revenue and EPS?
Karyopharm Therapeutics reported revenue of $35.1M and eps of $-1.24 for Q1 2026.
Did Karyopharm Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $31.4M by $3.7M. EPS beat the consensus estimate of $-1.45 by $0.21.
How did Karyopharm Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 16.8% from $30.0M a year earlier and eps grew 55.2% from $-2.77.
Where can I find Karyopharm Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-222808) and the 10-Q periodic report (0001193125-26-222827) directly on SEC EDGAR. The filing index links above go to sec.gov.